Codexis, Inc. (CDXS)
1.43
0.00 (0.00%)
USD |
NASDAQ |
Sep 09, 16:00
1.46
+0.03
(+2.10%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 130.68M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -41.63% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 1.670 |
| Price to Book Value | 3.965 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 2.202 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 97.65% |
Profile
| Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA. |
| URL | http://www.codexis.com |
| Investor Relations URL | https://www.codexis.com/investors |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Small Cap Value |
| Next Earnings Release | Nov. 05, 2026 (est.) |
| Last Earnings Release | Aug. 11, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA. |
| URL | http://www.codexis.com |
| Investor Relations URL | https://www.codexis.com/investors |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Small Cap Value |
| Next Earnings Release | Nov. 05, 2026 (est.) |
| Last Earnings Release | Aug. 11, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |